The US FDA has approved Mitapivat (Aqvesme), the first oral therapy for anemia in adults with alpha or beta thalassemia, offering a new treatment beyond blood transfusions. This drug activates energy production in red blood cells, improving hemoglobin levels and reducing fatigue. While trials showed significant benefits, it awaits Indian regulatory approval.
